ArticlesTreatment of extensively drug-resistant tuberculosis in Tomsk, Russia: a retrospective cohort study
Introduction
Every year an estimated 490 000 new cases of multidrug resistant (MDR) tuberculosis arise worldwide, with a prevalence that is thought to be three times greater than this number.1, 2 MDR tuberculosis—caused by strains of Mycobacterium tuberculosis that are resistant to isoniazid and rifampin, the backbone of first-line treatment against tuberculosis—is more difficult and costly to treat than non-drug-resistant tuberculosis.3, 4 However, extensively drug-resistant (XDR) tuberculosis is an even greater threat to control of the disease. XDR tuberculosis is a subgroup of MDR tuberculosis, which is also resistant to the most effective second-line drugs against tuberculosis: any second-line aminoglycoside or capreomycin, and any fluoroquinolone.5, 6 Although the worldwide burden of XDR tuberculosis is unknown, 7% of isolates of MDR tuberculosis referred to supranational reference laboratories from 2000 to 2004 were XDR cases.1
Scarce therapeutic options and high mortality rates associated with XDR tuberculosis are a concern. A report of an outbreak of XDR tuberculosis in 53 HIV-positive patients in the province of KwaZulu Natal in the Republic of South Africa, during which 52 patients died after about 16 days from diagnosis of tuberculosis, has been a warning for the global tuberculosis community of the dangers of allowing drug resistance to flourish unchecked.7 Other reports from non-HIV-infected patients have reinforced the alarm.8, 9, 10, 11, 12, 13
Although XDR tuberculosis is referred to by some as being untreatable, aggressive clinical and programmatic management can greatly improve the outcome of the disease, which provides hope to the many infected patients. The aim of this study is to describe the clinical characteristics, management, and outcomes of patients treated for MDR and XDR tuberculosis in Tomsk, Russia.
Section snippets
Study setting
Tomsk Oblast is located in western Siberia, Russia, and has about 1·1 million inhabitants, roughly half of whom live in remote rural villages. Between 1998 and 2002, rates of MDR tuberculosis in Tomsk rose from 6·5% to 13·7% for newly detected cases, and from 26·7% to 43·6% for previously treated cases. During this time, Tomsk had implemented DOTS (directly observed treatment, short-course), the treatment strategy of WHO for non-drug-resistant tuberculosis, consisting of short-course
Results
Of the 636 patients who had treatment against MDR tuberculosis in the study period, 608 had documented baseline MDR tuberculosis and 28 were treated for presumed MDR tuberculosis on the basis of treatment or contact history, or MDR tuberculosis diagnosed before moving to Tomsk. These 28 patients are excluded from the analysis. 29 patients (4·8%) met the definition of XDR tuberculosis before starting treatment for MDR tuberculosis. The proportion of patients with XDR tuberculosis did not vary by
Discussion
We have shown that, although treatment outcomes were worse in patients with XDR tuberculosis than those in patients with MDR tuberculosis who were infected with strains that were susceptible to fluoroquinolones and at least one of the parenteral drugs, 48% of patients with XDR tuberculosis—often termed untreatable in press reports—responded favourably to treatment. Although our results for treatment outcomes were similar to those reported elsewhere,13, 26 one major difference was that the
References (41)
- et al.
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural areas of South Africa
Lancet
(2006) - et al.
Programmes and principles in treatment of multidrug-resistant tuberculosis
Lancet
(2004) - et al.
From multidrug-resistant tuberculosis to DOTS expansion and beyond: making the most of a paradigm shift
Tuberculosis
(2003) - et al.
Pulmonary resection for multidrug-resistant tuberculosis
J Thorac Cardiovasc Surg
(2001) Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world: report no 4
(2008)The Global MDR-TB & XDR-TB Response Plan 2006–2007
(2007)- et al.
Managing multidrug-resistant tuberculosis
J Respin Dis
(2000) - et al.
Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries
JAMA
(2000) Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs—worldwide, 2000–2004
MMWR Morb Mortal Wkly Rep
(2006)Report of the meeting of the Global Task Force on XDR-TB
(2006)
Worldwide emergence of extensively drug-resistant tuberculosis
Emerg Infect Dis
Extensively drug-resistant tuberculosis: 2 years of surveillance in Iran
Clin Infect Dis
Extensively drug-resistant tuberculosis, Italy and Germany
Emerg Infect Dis
Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis
Clin Infect Dis
Extensively drug-resistant tuberculosis—United States, 1993–2006
MMWR Morb Mortal Wkly Rep
Clinical and operational value of the extensively drug-resistant tuberculosis definition
Eur Respir J
Comparison of the effectiveness of WHO short-course chemotherapy and standard Russian antituberculous regimens in Tomsk, western Siberia
Lancet
Frequency of recurrence among MDR-TB cases “successfully” treated with standardised short-course chemotherapy
Int J Tuberc Lung Dis
Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB
Int J Tuberc Lung Dis
Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance
PLoS Med
Cited by (156)
Phototherapy and optical waveguides for the treatment of infection
2021, Advanced Drug Delivery ReviewsHighly efficient and selective antimicrobial isonicotinylhydrazide-coated polyoxometalate-functionalized silver nanoparticles
2019, Colloids and Surfaces B: BiointerfacesBiophysical and biochemical characterization of Rv3405c, a tetracycline repressor protein from Mycobacterium tuberculosis
2018, Biochemical and Biophysical Research CommunicationsCitation Excerpt :Though the current treatment regimen is being used for more than 40 years [2,3], its safety and efficiency rate is high, the long duration of treatment and adverse effects are still major challenges in TB management. The emergence of drug resistant forms of TB especially the XDR and TDR-TB cases has made the problem even worse [4,5]. Identification of new biomarkers for diagnosis, vaccine candidates, drug targets and drugs to combat the infection in order to achieve the “END TB 2030” vision is a primary aim of research in this area.